-
Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)
… for dopamine-producing neurons in the brain. Impact on Diagnosis/Treatment of Parkinson’s disease: Positive … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Modulation of Glycine for the Treatment of Parkinson’s Disease
… improved pharmacokinetic properties in the body. Impact on Diagnosis/Treatment of Parkinson’s disease: Treating … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Development of Novel Brain-penetrant Inflammasome Inhibitors as Potential Therapeutics for Parkinson’s Disease
… and the corresponding nervous system pathology. Impact on Diagnosis/Treatment of Parkinson’s disease: We expect that … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Preclinical Studies of Compounds that Block Alpha-synuclein Aggregation by Antagonizing the Sigma-2 Receptor
… sigma-2 receptor and disease modification. Impact on Diagnosis/Treatment of Parkinson’s disease: If successful, a … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Phase 1b Trial to Assess the Safety and Efficacy of Dopamine Cell Transplants in Parkinson’s Disease Linked to Mutations in Parkin
… elect to be grafted on the contralateral side). Impact on Diagnosis/Treatment of Parkinson’s Disease: Confirming the … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …
-
Targeting the Interaction of Alpha-synuclein with Lipids as a Therapeutic for Parkinson’s Disease
… of this enzyme is now in clinical trials for PD. Impact on Diagnosis/Treatment of Parkinson’s disease: Several studies … Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies …